Infigratinib靶向的FGFR3（成纤维细胞生长因子受体3）正是驱动ACH疾病发生的关键靶点，2月12日，BridgeBio公布Infigratinib在ACH中取得的首个具有统计学显著改善意义的3期顶线结果，公司计划下半年向FDA提交新药申请。
OpenAI CEO Sam Altman told his employees in a memo on Thursday that the company would push for the same limitations on autonomous weapons and mass surveillance that Anthropic has, according to Axios.。im钱包官方下载对此有专业解读
。关于这个话题，heLLoword翻译官方下载提供了深入分析
More Technology of BusinessAI ready: The advantages of being a young entrepreneur
.pipeThrough(serialize) // even more buffers...。关于这个话题，51吃瓜提供了深入分析